Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.

Date publication

janvier 2015

Journal

Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GARBAR Christian , Pr BENSUSSAN Armand

Tous les auteurs :
Mombelli S, Kwiatkowski F, Abrial C, Wang-Lopez Q, de Boissieu P, Garbar C, Bensussan A, Curé H

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25573741

Résumé

Neoadjuvant chemotherapy (NACT) allows for a more frequent use of breast-conservative surgery; it is also an in vivo model of individual tumor sensitivity which permits to determine new prognostic factors to personalize the therapeutic approach.

Mots clés

Adult, Aged, Aged, 80 and over, Anthracyclines, administration & dosage, Antineoplastic Combined Chemotherapy Protocols, administration & dosage, Breast Neoplasms, drug therapy, Carcinoma, Ductal, Breast, drug therapy, Chemotherapy, Adjuvant, Confounding Factors (Epidemiology), Cyclophosphamide, administration & dosage, Disease-Free Survival, Drug Administration Schedule, Epirubicin, administration & dosage, Female, Fluorouracil, administration & dosage, Follow-Up Studies, France, epidemiology, Humans, Kaplan-Meier Estimate, Lymphatic Metastasis, Mastectomy, Segmental, Middle Aged, Neoadjuvant Therapy, methods, Neoplasm Staging, Neoplasm, Residual, epidemiology, Prognosis, Retrospective Studies, Risk Factors, Taxoids, administration & dosage, Treatment Outcome

Référence

Oncology. 2015 ;88(5):261-72